1 Hypothesis, Multiple Implications: Adenoviral Vector Vaccines and Thrombosis with Thrombocytopenia Syndrome
The RPTH Journal (Research and Practice in Thrombosis and Haemostasis) shared an insightful post on LinkedIn:
”This new study investigates adenoviral vector vaccine-associated thrombosis/thrombocytopenia risk.
- Adenoviral vectors can infect megakaryocytes
- Concurrent infection may increase chemokine receptor expression
Senior Author: Joseph Torresi”
Read the full article here.
In the article ”Adenovirus vectors can infect mouse megakaryocytes – implications for vaccine-induced thrombosis/thrombocytopenia” by Simon Collett, Joseph Torresi et al. in the RPTH Journal, a potential role of adenoviral vector vaccines in inducing TTS is discussed.
Adenoviruses, adenoviral vector-based vaccines, and gene delivery systems have been associated with thrombosis with thrombocytopenia syndrome (TTS), a rare but serious complication.
The precise mechanisms underlying this condition remain unclear.
It was previously hypothesized that megakaryocytes (MKs)—the precursor cells responsible for platelet production—play a central role in the development of adenovirus- or vector-induced TTS.
Emerging evidence supports the notion that MKs are a heterogeneous population, including subsets with distinct immune-related functions.
This study demonstrates that adenoviral infection preferentially targets higher-ploidy CD41⁺CD42⁺ MKs and those expressing high levels of CXCR4 (CXCR4^hi).
These findings implicate specific MK subsets and surface receptors in the cellular response to adenoviral exposure and provide a potential mechanistic link to thrombocytopenia and thrombotic events observed post-vaccination or gene therapy.

Find all the latest scientific advancements in the World of Thrombosis posted in Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight